Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Http Dx Doi Org 10 1002 Adma 201104290"

11:16 EDT 23rd April 2014 | BioPortfolio

Matching Channels

Freiberg Infraction

Freiberg's disease is an osteochondrosis of the metatarsal head, most commonly occurring in young athletes older than 12 years who perform on their toes in either sprinting or jumping activities...

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to: http://www.bioportfolio.com/news/article/987636/Pediculosis-Louse-Lice-Treatment.html    

Pediculosis - louse (lice) infestation

   To view our most recent article on Lice Infestation please go to: http://www.bioportfolio.com/news/article/987568/Pediculosis-Louse-Lice-Infestation.html 

Pediculosis - louse (lice) diagnosis

   To view our most recent articals on Lice Diagnosis please view: http://www.bioportfolio.com/news/article/987588/Pediculosis-Louse-Lice-Diagnosis.html

G-protein-coupled receptors (GPCRs)

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers th...

Matching News

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious...

ADMA completes debt financing

Capricor Therapeutics pharma partners with Janssen Biotech

Capricor Therapeutics pharma partners in a collaboration agreement and exclusive license option with Janssen Biotech. Capricor and Janssen pharma partners on the development of Capricor’s cell t...

Capricor jumps on cell therapy deal with Janssen

Capricor Therapeutics Inc. (OTCQB:CAPR) partnered with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) to develop Capricor's cell therapy programs for cardiologic applications, inc...

CAP-1002: Phase I/II ongoing

ADMA Biologics to Present at the Oppenheimer 24th Annual Healthcare Conference

ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and...

ADMA Biologics to Present Company Overview at the 13th Annual Needham Healthcare Conference

ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and...

ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters

ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment an...

Matching PubMed Articles

Rejoinder.

This is the reply to the discussion of the two companion articles on the theory and application of "probability estimation with machine learning methods for dichotomous and multicategory outcome" by K...

ADMA Levels and Arginine/ADMA Ratios Reflect Severity of Disease and Extent of Inflammation After Subarachnoid Hemorrhage.

Subarachnoid hemorrhage (SAH) is characterized by an inflammatory response that might induce endothelial dysfunction. The aim of this study was to evaluate if ADMA and arginine/ADMA ratios after SAH (...

The Endothelial ADMA/NO Pathway in Hypoxia-Related Chronic Respiratory Diseases.

Since its discovery, many adhere to the view that asymmetric dimethylarginine (ADMA), as an inhibitor of the synthesis of nitric oxide (NO), contributes to the pathogenesis of various diseases. Partic...

Biological Functional Relevance of Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease.

There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) may contribute to endothelial dysfunction. Studies in animal models as well a...

Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria.

Background. Nitric oxide (NO) bioavailability is impaired in children and adults with severe falciparum malaria (SM). Asymmetric-dimethylarginine (ADMA) limits NO production by inhibiting NO synthas...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement